Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1992 Nov;47(11):932–936. doi: 10.1136/thx.47.11.932

Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.

S J Gallacher 1, J A Fenner 1, K Anderson 1, F M Bryden 1, S W Banham 1, F C Logue 1, R A Cowan 1, I T Boyle 1
PMCID: PMC464099  PMID: 1465751

Abstract

BACKGROUND: Bisphosphonates have been shown to be effective agents in the treatment of postmenopausal osteoporosis. Because corticosteroid associated osteoporosis is often associated with increased bone turnover, the effect of intermittent intravenous infusions of pamidronate on this condition has been investigated. METHODS: Seventeen patients (five male) with chronic corticosteroid dependent lung disease (15 asthma, two sarcoidosis) were treated with infusions of 30 mg pamidronate once every three months for one year. These patients had been taking an average of 14 (range 7.5-40) mg prednisolone a day for an average of 14 (range 3-30) years. Bone density measurements, by dual energy x ray absorptiometry, and radiography of the dorsolumbar spine were carried out before and one year after treatment. Bone formation was assessed by measurement of serum alkaline phosphatase and bone resorption by measurement of the fasting urinary hydroxyproline: creatinine ratio at the same time as densitometry and radiography were performed. RESULTS: Pretreatment density of L2-4 and the neck of the femur was significantly lower in these patients compared with a cohort of 100 age and sex matched controls (L2-4 (mean (SEM)): 0.906 (0.050) g/cm2 v 1.142 (0.016) g/cm2; neck of femur: 0.793 (0.030) g/cm2 v 0.936 (0.013)) g/cm2. After treatment there was a significant fall in serum alkaline phosphatase activity from (mean (SEM)) 220 (16) U/1 to 174 (9) U/1 (normal 80-280 U/1) and in the fasting urinary hydroxyproline:creatinine ratio from (mean (SEM) 0.040 (0.006) to 0.024 (0.003) (normal < 0.033). A significant rise was noted in L2-4 density to 0.927 (0.047) g/cm2; mean rise of 3.4%). No change was noted in density of the neck of the femur. CONCLUSIONS: Intermittent infusions of intravenous pamidronate would seem to be effective in both reducing turnover of bone and increasing bone density in corticosteroid induced osteoporosis associated with chronic lung disease. Longer term controlled studies are indicated.

Full text

PDF
932

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adinoff A. D., Hollister J. R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983 Aug 4;309(5):265–268. doi: 10.1056/NEJM198308043090502. [DOI] [PubMed] [Google Scholar]
  2. Boyce B. F., Smith L., Fogelman I., Johnston E., Ralston S., Boyle I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet. 1984 Apr 14;1(8381):821–824. doi: 10.1016/s0140-6736(84)92272-4. [DOI] [PubMed] [Google Scholar]
  3. Compston J. E., Horton L. W., Laker M. F., Ayers A. B., Woodhead J. S., Bull H. J., Gazet J. C., Pilkington T. R. Bone disease after jejuno-ileal bypass for obesity. Lancet. 1978 Jul 1;2(8079):1–4. doi: 10.1016/s0140-6736(78)91318-1. [DOI] [PubMed] [Google Scholar]
  4. Dempster D. W., Arlot M. A., Meunier P. J. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int. 1983 Jul;35(4-5):410–417. doi: 10.1007/BF02405069. [DOI] [PubMed] [Google Scholar]
  5. Fogelman I., Smith L., Mazess R., Wilson M. A., Bevan J. A. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) 1986 Jan;24(1):57–62. doi: 10.1111/j.1365-2265.1986.tb03254.x. [DOI] [PubMed] [Google Scholar]
  6. Gallacher S. J., Boyce B. F., Patel U., Jenkins A., Ralston S. H., Boyle I. T. Clinical experience with pamidronate in the treatment of Paget's disease of bone. Ann Rheum Dis. 1991 Dec;50(12):930–933. doi: 10.1136/ard.50.12.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gallacher S. J., Ralston S. H., Fraser W. D., Dryburgh F. J., Cowan R. A., Logue F. C., Boyle I. T. A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia. Bone Miner. 1991 Dec;15(3):249–256. doi: 10.1016/0169-6009(91)90130-r. [DOI] [PubMed] [Google Scholar]
  8. Gallacher S. J., Ralston S. H., Patel U., Boyle I. T. Side-effects of pamidronate. Lancet. 1989 Jul 1;2(8653):42–43. doi: 10.1016/s0140-6736(89)90277-8. [DOI] [PubMed] [Google Scholar]
  9. Goverde B. C., Veenkamp F. J. Routine assay of total urinary hydroxyproline based on resin-catalysed hydrolysis. Clin Chim Acta. 1972 Oct;41:29–40. doi: 10.1016/0009-8981(72)90492-5. [DOI] [PubMed] [Google Scholar]
  10. Hahn T. J., Halstead L. R., Baran D. T. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab. 1981 Jan;52(1):111–115. doi: 10.1210/jcem-52-1-111. [DOI] [PubMed] [Google Scholar]
  11. Klein R. G., Arnaud S. B., Gallagher J. C., Deluca H. F., Riggs B. L. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest. 1977 Jul;60(1):253–259. doi: 10.1172/JCI108762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Logue F. C., Perry B., Chapman R. S., Milne I., James K., Beastall G. H. A two-site immunoradiometric assay for PTH(1-84) using N and C terminal specific monoclonal antibodies. Ann Clin Biochem. 1991 Mar;28(Pt 2):160–166. doi: 10.1177/000456329102800207. [DOI] [PubMed] [Google Scholar]
  13. Lukert B. P., Raisz L. G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990 Mar 1;112(5):352–364. doi: 10.7326/0003-4819-112-5-352. [DOI] [PubMed] [Google Scholar]
  14. Mazess R., Collick B., Trempe J., Barden H., Hanson J. Performance evaluation of a dual-energy x-ray bone densitometer. Calcif Tissue Int. 1989 Mar;44(3):228–232. doi: 10.1007/BF02556569. [DOI] [PubMed] [Google Scholar]
  15. Meunier P. J., Dempster D. W., Edouard C., Chapuy M. C., Arlot M., Charhon S. Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome. Adv Exp Med Biol. 1984;171:191–200. [PubMed] [Google Scholar]
  16. Ralston S. H., Cowan R. A., Robertson A. G., Gardner M. D., Boyle I. T. Circulating vitamin D metabolites and hypercalcaemia of malignancy. Acta Endocrinol (Copenh) 1984 Aug;106(4):556–563. doi: 10.1530/acta.0.1060556. [DOI] [PubMed] [Google Scholar]
  17. Ralston S. H., Gardner M. D., Dryburgh F. J., Jenkins A. S., Cowan R. A., Boyle I. T. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet. 1985 Oct 26;2(8461):907–910. doi: 10.1016/s0140-6736(85)90848-7. [DOI] [PubMed] [Google Scholar]
  18. Reid I. R., King A. R., Alexander C. J., Ibbertson H. K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988 Jan 23;1(8578):143–146. doi: 10.1016/s0140-6736(88)92721-3. [DOI] [PubMed] [Google Scholar]
  19. Sakakura M., Takebe K., Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab. 1975 May;40(5):774–779. doi: 10.1210/jcem-40-5-774. [DOI] [PubMed] [Google Scholar]
  20. Smith R., Russell R. G., Bishop M. Diphosphonates and Page's disease of bone. Lancet. 1971 May 8;1(7706):945–947. doi: 10.1016/s0140-6736(71)91447-4. [DOI] [PubMed] [Google Scholar]
  21. Storm T., Thamsborg G., Steiniche T., Genant H. K., Sørensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. doi: 10.1056/NEJM199005033221803. [DOI] [PubMed] [Google Scholar]
  22. Suzuki Y., Ichikawa Y., Saito E., Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism. 1983 Feb;32(2):151–156. doi: 10.1016/0026-0495(83)90221-4. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES